Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKaracan, Meriç
dc.contributor.authorErdem, Erkan
dc.contributor.authorUsta, Akın
dc.contributor.authorArvas, Ayşe
dc.contributor.authorCebi, Ziya
dc.contributor.authorÇamlıbel, Teksen
dc.date.accessioned2019-09-24T11:29:27Z
dc.date.available2019-09-24T11:29:27Z
dc.date.issued2017en_US
dc.identifier.issn0379-5284
dc.identifier.urihttps://doi.org/10.15537/smj.2017.6.17717
dc.identifier.urihttps://hdl.handle.net/20.500.12462/6458
dc.descriptionUsta, Akın (Balikesir Author)en_US
dc.description.abstract"Objectives: To compare the live birth rates and moderate/severe ovarian hyperstimulation syndrome (OHSS) rates of 2 different approaches using gonadotropin-releasing hormone (GnRH) agonist triggering in high responder women. Methods: A retrospective cohort study was performed to evaluate intracytoplasmic sperm injection (ICSI) and embryo transfer (ET) outcomes in high responder women who underwent ovulation induction with a GnRH antagonist protocol between April 2011 and March 2015. In group 1 (n=74), GnRH agonist was used for ovulation triggering with the concomitant use of 1500 IU of urinary human chorionic gonadotropin (hCG) immediately after oocyte retrieval followed by fresh ET and standard luteal support. In group 2 (n=48), GnRH agonist was used for triggering after freezing all embryos and subsequent frozen/thawed embryo transfer (FET); this approach is considered the ""freeze-all"" approach. Results: Baseline characteristics were similar between the groups. The clinical pregnancy rates for group 1 was 45.9% and group 2 was 43.8% (p=0.812, chi-squared test) and live birth rates for group 1 was 40.5% and for group 2 41.7% (p=0.902, chi-squared test) were comparable between groups. In group 1, late-onset OHSS was observed (one severe case and one moderate case) in 2 patients (2.7%). In group 2, none of the patients experienced moderate/severe OHSS. Conclusion: The live birth rate with GnRH agonist triggering and concomitant use of 1500 IU of hCG immediately after oocyte retrieval was similar to that obtained with the freeze-all approach and FET in a subsequent cycle. The administration of a low dose of hCG in GnRH agonist trigger cycles caused moderate/severe OHSS in 2.7% of the patients."en_US
dc.language.isoengen_US
dc.publisherSaudi Med Jen_US
dc.relation.isversionof10.15537/smj.2017.6.17717en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOvarian Hyperstimulation Syndromeen_US
dc.subjectInduce Oocyte Maturationen_US
dc.subjectGnrh Antagonist Cyclesen_US
dc.subjectHigh-Risk Patientsen_US
dc.subjectPregnancy Ratesen_US
dc.subjectHcgen_US
dc.subjectFertilizationen_US
dc.subjectStimulationen_US
dc.subjectOvulationen_US
dc.subjectVitrificationen_US
dc.titleGonadotropin-releasing hormone agonist triggering with concomitant administration of low doses of human chorionic gonadotropin or a freeze-all strategy in high respondersen_US
dc.typearticleen_US
dc.relation.journalSaudi Medical Journalen_US
dc.contributor.departmentTıp Fakültesien_US
dc.identifier.volume38en_US
dc.identifier.issue6en_US
dc.identifier.startpage586en_US
dc.identifier.endpage591en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster